deltatrials
Unknown PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03310632

Determine Function of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer

A Phase I/II Study to Determine the MTD and to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer

Sponsor: Covance

Conditions Pancreatic Neoplasm
Interventions Antroquinonol
Updated 18 times since 2017 Last updated: Sep 23, 2024 Started: Dec 1, 2017 Primary completion: Nov 1, 2023 Completion: Dec 31, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Pancreatic Neoplasm and is currently ongoing. Covance leads this study, which shows 18 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Oct 2017 – ~Dec 2017 · 2 months · monthly snapshot~Dec 2017 – ~May 2018 · 5 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jun 2019 · 12 months · monthly snapshot~Jun 2019 – ~Aug 2020 · 14 months · monthly snapshot~Aug 2020 – ~Oct 2020 · 2 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshot~Oct 2021 – ~Sep 2022 · 11 months · monthly snapshot~Sep 2022 – ~Oct 2023 · 13 months · monthly snapshot~Oct 2023 – ~Mar 2024 · 5 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Sep 2025 · 11 months · monthly snapshot~Sep 2025 – ~Dec 2025 · 3 months · monthly snapshot~Dec 2025 – ~Mar 2026 · 3 months · monthly snapshot~Mar 2026 – present · 5 months · monthly snapshot

Change History

18 versions recorded

  1. Mar 2026 — Present [monthly]

    Unknown PHASE1/PHASE2

    Status: Active Not Recruiting → Unknown

  2. Dec 2025 — Mar 2026 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  3. Sep 2025 — Dec 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  4. Oct 2024 — Sep 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  5. Sep 2024 — Oct 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

▶ Show 13 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  2. Mar 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Oct 2023 — Mar 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Sep 2022 — Oct 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Oct 2021 — Sep 2022 [monthly]

    Recruiting PHASE1_PHASE2

  6. Jan 2021 — Oct 2021 [monthly]

    Recruiting PHASE1_PHASE2

  7. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  8. Aug 2020 — Oct 2020 [monthly]

    Recruiting PHASE1_PHASE2

  9. Jun 2019 — Aug 2020 [monthly]

    Recruiting PHASE1_PHASE2

  10. Jun 2018 — Jun 2019 [monthly]

    Recruiting PHASE1_PHASE2

  11. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  12. Dec 2017 — May 2018 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  13. Oct 2017 — Dec 2017 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Covance
  • Golden Biotechnology Corporation
Data source: Golden Biotechnology Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations